

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|---|---|
| (51) International Patent Classification ⁶ : C12N 15/00, 15/12, C07K 14/00, 14/435, 7/00 | A1 | (11) International Publication Number: WO 99/50405 (43) International Publication Date: 7 October 1999 (07.10.99) |
| (21) International Application Number: PCT/US99/06946 (22) International Filing Date: 30 March 1999 (30.03.99) (30) Priority Data: 60/080,110 31 March 1998 (31.03.98) US 09/280,591 29 March 1999 (29.03.99) US (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 Cambridge Park Drive, Cambridge, MA 02140 (US). (72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US). McCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LaVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). EVANS, Cheryl; 18801 Bent Willow Circle, Germantown, MD 20874 (US). MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US). STEININGER, Robert, J. II; 100 Reed Street, Cambridge, MA 02140 (US). (74) Agent: MANDRAGOURAS, Amy, A.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US). | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> | |
| (54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM | | |
| (57) Abstract Novel polynucleotides and the proteins encoded thereby are disclosed. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | | | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Licchtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

5

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

10

This application is a continuation-in-part of provisional application Ser. No. 60/080,110, filed March 31, 1998, which is incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques
25 clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader
30 sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the
35 polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174;
- 10 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;
- 15 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;
- 20 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
- 25 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 30 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:1.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174; the nucleotide sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174; the nucleotide sequence of the full-length protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715; or the
5 nucleotide sequence of a mature protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715. In further preferred
10 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having
15 biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 20 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 25 (aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
 - (ab) the nucleotide sequence of the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 30 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(bb) the nucleotide sequence of the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:2;

(b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and

(c) the amino acid sequence encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ
ID NO:2 having biological activity, the fragment comprising the amino acid sequence from
10 amino acid 321 to amino acid 330 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;

15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 202 to nucleotide 414;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 370 to nucleotide 414;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ct547_2 deposited under accession
20 number ATCC 98715;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;

(f) a polynucleotide comprising the nucleotide sequence of a mature
25 protein coding sequence of clone ct547_2 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;

(h) a polynucleotide encoding a protein comprising the amino acid
30 sequence of SEQ ID NO:4;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 202 to nucleotide 414; the nucleotide sequence of SEQ ID NO:3 from nucleotide 370 to nucleotide 414; the nucleotide sequence of the full-length protein coding sequence of clone ct547_2 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone ct547_2 deposited
15 under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological
20 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:4.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(ab) the nucleotide sequence of the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

5 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

10 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

15 (bb) the nucleotide sequence of the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated
25 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 202 to nucleotide 414, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 202 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 202 to
30 nucleotide 414. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 370 to nucleotide 414, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from

nucleotide 370 to nucleotide 414, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 370 to nucleotide 414.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone en553_1 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone en553_1 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

5 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

10 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

15 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415; the nucleotide sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415; the nucleotide sequence of the full-length protein coding sequence of clone en553_1 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone en553_1 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715. In further preferred
25 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having
30 biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415, and extending

contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nn296_2 deposited under accession number ATCC 98715;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715;

(e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nn296_2 deposited under accession number ATCC 98715;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:7.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202; the nucleotide sequence of the full-length protein coding sequence of clone nn296_2 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone nn296_2 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having

biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:7.

5 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize
10 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:7, but excluding the poly(A) tail at the
3' end of SEQ ID NO:7; and

(ab) the nucleotide sequence of the cDNA insert of clone
nn296_2 deposited under accession number ATCC 98715;

15 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

20 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the
25 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone
nn296_2 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

30 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to

a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202, and extending
5 contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202.

In other embodiments, the present invention provides a composition comprising
10 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
15 (c) the amino acid sequence encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the
20 amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 175 to amino acid 184 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an
25 isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:9 from nucleotide 597 to nucleotide 704;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nq27_13 deposited under accession number ATCC 98715;

- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nq27_13 deposited under accession number
5 ATCC 98715;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- 10 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
- 15 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 20 (l) a polynucleotide which encodes a species homologue of the protein of (g)-(j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and
- (n) a polynucleotide that hybridizes under stringent conditions to any
25 one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:9.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 597 to nucleotide 704; the nucleotide sequence of the full-length protein coding sequence of clone nq27_13 deposited under accession number ATCC
30 98715; or the nucleotide sequence of a mature protein coding sequence of clone nq27_13 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein

comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(ab) the nucleotide sequence of the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(bb) the nucleotide sequence of the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 597 to nucleotide 704, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 597 to nucleotide 704, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 597 to nucleotide 704.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence of SEQ ID NO:32;
- (d) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
- (e) the amino acid sequence encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 13 to amino acid 22 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 44 to nucleotide 475;

5 (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk65_4 deposited under accession number ATCC 98715;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

10 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pk65_4 deposited under accession number ATCC 98715;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

15 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;

20 (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

25 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:11.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 44 to nucleotide 475; the nucleotide sequence of the full-length protein coding sequence of clone pk65_4 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone pk65_4 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

of clone pk65_4 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

- 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the
- 10 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 44 to nucleotide 475, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 44 to nucleotide 475, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide
- 15 44 to nucleotide 475.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- 20 (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such

25 protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ

30 ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 67 to amino acid 76 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590;

5 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715;

10 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715;

15 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

20 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

25 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

30 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:13.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590; the nucleotide sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590; the nucleotide sequence of the full-length protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715; or the

nucleotide sequence of a mature protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715. In further preferred
5 embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having
10 biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

Further embodiments of the invention provide isolated polynucleotides produced
15 according to a process selected from the group consisting of:

(a) a process comprising the steps of:
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

20 (aa) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

(ab) the nucleotide sequence of the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;

25 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13; and

(bb) the nucleotide sequence of the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

5 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13, but excluding the poly(A) tail at the 3' end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:14;

(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and

(c) the amino acid sequence encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 46 to amino acid 55 of SEQ ID NO:14.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- 10 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715;
- 15 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- 25 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 30 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:15.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223; the nucleotide sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223; the nucleotide sequence of the full-length protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 333 to amino acid 342 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:15; and
 - (ab) the nucleotide sequence of the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5

(ba) SEQ ID NO:15; and

(bb) the nucleotide sequence of the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

10

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

30

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

(c) the amino acid sequence encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred
5 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ
10 ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 333 to amino acid 342 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;

15 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 381 to nucleotide 1121;

20 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm4_13 deposited under accession number ATCC 98715;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

25 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pm4_13 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

30 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

5 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121; the nucleotide sequence of SEQ ID NO:17 from nucleotide 381 to nucleotide 1121; the nucleotide sequence of the full-length protein coding sequence of clone pm4_13 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone pm4_13 deposited
15 under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological
20 activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 149 to amino acid 158 of SEQ ID NO:18.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:17.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(ab) the nucleotide sequence of the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and

(bb) the nucleotide sequence of the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 381 to nucleotide 1121, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from

nucleotide 381 to nucleotide 1121, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 381 to nucleotide 1121.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 149 to amino acid 158 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt326_4 deposited under accession number ATCC 98715;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt326_4 deposited under accession number ATCC 98715;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:19.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953; the nucleotide sequence of the full-length protein coding sequence of clone pt326_4 deposited under accession number ATCC 98715; or the nucleotide sequence of a mature protein coding sequence of clone pt326_4 deposited under accession number ATCC 98715. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 317 to amino acid 326 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and

(ab) the nucleotide sequence of the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and

(bb) the nucleotide sequence of the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953, to a nucleotide

sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:20;
- (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 317 to amino acid 326 of SEQ ID NO:20.

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

10

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone
15 in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have
20 determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation
25 proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Clone "cc359_4"

30

A polynucleotide of the present invention has been identified as clone "cc359_4". cc359_4 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cc359_4 is a full-length clone,

including the entire coding sequence of a secreted protein (also referred to herein as "cc359_4 protein").

The nucleotide sequence of cc359_4 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cc359_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Amino acids 29 to 41 of SEQ ID NO:2 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 42. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cc359_4 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cc359_4 should be approximately 2200 bp.

The nucleotide sequence disclosed herein for cc359_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cc359_4 demonstrated at least some similarity with sequences identified as H23117 (ym51g12.s1 Homo sapiens cDNA clone 51970 3'). Based upon sequence similarity, cc359_4 proteins and each similar protein or peptide may share at least some activity. The cc359_4 protein sequence contains four chaoptin domains (at amino acids 94-115, 118-139, 142-163, and 261-282 of SEQ ID NO:2). Chaoptin is a cell-surface glycoprotein required for *Drosophila* photoreceptor cell morphogenesis. Chaoptin is largely composed of 41 potentially amphipathic repeats. Chaoptin repeats that have been reported in both yeast and human proteins are remarkably similar, suggesting their general importance as a structural and/or functional motif. Additionally, the cc359_4 protein was found to contain a leucine zipper motif. The TopPredII computer program predicts five potential transmembrane domains within the cc359_4 protein sequence, centered around amino acids 20, 410, 490, 530, and 590 of SEQ ID NO:2, respectively.

Clone "ct547_2"

A polynucleotide of the present invention has been identified as clone "ct547_2". ct547_2 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ct547_2 is a full-length clone,

including the entire coding sequence of a secreted protein (also referred to herein as "ct547_2 protein").

The nucleotide sequence of ct547_2 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ct547_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 44 to 56 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 57. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ct547_2 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ct547_2 should be approximately 1600 bp.

The nucleotide sequence disclosed herein for ct547_2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ct547_2 demonstrated at least some similarity with sequences identified as AA428546 (zw47d03.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 773189 5'), R20032 (yg31g04.r1 Homo sapiens cDNA clone 34069 5'), R27350 (yh53c12.r1 Homo sapiens cDNA clone 133462 5'), and R66971 (yi29e12.r1 Homo sapiens cDNA clone 140686 5'). Based upon sequence similarity, ct547_2 proteins and each similar protein or peptide may share at least some activity.

Clone "en553_1"

A polynucleotide of the present invention has been identified as clone "en553_1". en553_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. en553_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "en553_1 protein").

The nucleotide sequence of en553_1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the en553_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 17 to 29 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature

of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the en553_1 protein. Another potential en553_1 reading frame and predicted amino acid sequence is encoded by basepairs 1334 to 1597 of SEQ ID NO:5 and is reported in SEQ ID

5 NO:31

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone en553_1 should be approximately 2675 bp.

The nucleotide sequence disclosed herein for en553_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and
10 FASTA search protocols. en553_1 demonstrated at least some similarity with sequences identified as No hits were found in the databases. The nucleotide sequence of en553_1 indicates that it may contain one or more copies of the following repetitive elements: Alu, MIR.

15 Clone "nn296_2"

A polynucleotide of the present invention has been identified as clone "nn296_2". nn296_2 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis
20 of computer analysis of the amino acid sequence of the encoded protein. nn296_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nn296_2 protein").

The nucleotide sequence of nn296_2 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper
25 reading frame and the predicted amino acid sequence of the nn296_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone nn296_2 should be approximately 4500 bp.

The nucleotide sequence disclosed herein for nn296_2 was searched against the
30 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nn296_2 demonstrated at least some similarity with sequences identified as AA054538 (zk83e02.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 489434 3'), AA175407 (ms80c06.r1 Soares mouse 3NbMS Mus musculus cDNA clone 617866 5' similar to WP R08C7.2 CE07425), AA510586 (vg33c05.r1 Soares mouse

mammary gland NbMMG Mus musculus cDNA clone 863144 5' similar to WP:R08C7.2 CE07425), C18077 (Human placenta cDNA 5'-end GEN-557B03), T24416 (Human gene signature HUMGS06449), and W74238 (zd02f09.r1 Pancreatic Islet Homo sapiens cDNA clone 339497 5'). The predicted amino acid sequence disclosed herein for nn296_2 was
5 searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted nn296_2 protein demonstrated at least some similarity to sequences identified as U61953 (cosmid R08C7 [Caenorhabditis elegans]). Based upon sequence similarity, nn296_2 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential
10 transmembrane domains within the nn296_2 protein sequence, one centered around amino acid 50 and another around amino acid 340 of SEQ ID NO:8. The nucleotide sequence of nn296_2 indicates that it may contain at least one repetitive element.

Clone "nq27_13"

15 A polynucleotide of the present invention has been identified as clone "nq27_13". nq27_13 was isolated from a human adult blood (erythroleukemia TF-1) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. nq27_13
20 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nq27_13 protein").

The nucleotide sequence of nq27_13 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the nq27_13 protein
25 corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Another potential nq27_13 reading frame and predicted amino acid sequence is encoded by basepairs 371 to 616 of SEQ ID NO:9 and is reported in SEQ ID NO:32.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone nq27_13 should be approximately 900 bp.

30 The nucleotide sequence disclosed herein for nq27_13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nq27_13 demonstrated at least some similarity with sequences identified as AA015599 (ze20h10.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 359587 3'), AA465112 (aa32c05.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone

IMAGE:814952 5'), AA628397 (af26a12.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032766 3'), AA628438 (af26e12.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1032814 3'), D79280 (Human aorta cDNA 5'-end GEN-213H05), and H81836 (ys68g11.r1 Homo sapiens cDNA clone 220004 5'). Based upon sequence
5 similarity, nq27_13 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain at the N-terminus of the nq27_13 protein sequence, centered around amino acid 13 of SEQ ID NO:10.

nq27_13 protein was expressed in a COS cell expression system, and an expressed
10 protein band of approximately 11 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "pk65_4"

A polynucleotide of the present invention has been identified as clone "pk65_4".
15 pk65_4 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pk65_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to
20 herein as "pk65_4 protein").

The nucleotide sequence of pk65_4 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pk65_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.

25 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pk65_4 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for pk65_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pk65_4 demonstrated at least some similarity with sequences
30 identified as AA309041 (EST179822 Colon carcinoma (Caco-2) cell line I Homo sapiens cDNA 5' end), AA316187 (EST187903 HCC cell line (matatasis to liver in mouse) II Homo sapiens cDNA 5' end), AA488843 (aa55a10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824826 3'), AF022811 (Mus musculus cornichon mRNA, complete cds), D16980 (Human HepG2 partial cDNA, clone hmd2a04m5), N44081 (yy32a02.r1 Homo

sapiens cDNA clone 272906 5' similar to PIR A56724 A56724 cni protein - fruit fly). The predicted amino acid sequence disclosed herein for pk65_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pk65_4 protein demonstrated at least some similarity to sequences
5 identified as AB006191 (cornichon-like protein [Mus musculus]), AF022811 (cornichon [Mus musculus]), and U28069 (cni gene product [Drosophila melanogaster]). Based upon sequence similarity, pk65_4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the pk65_4 protein sequence, centered around amino
10 acids 16, 67, and 133 of SEQ ID NO:12, respectively.

pk65_4 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 15 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

15 Clone "pk855_1"

A polynucleotide of the present invention has been identified as clone "pk855_1". pk855_1 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis
20 of computer analysis of the amino acid sequence of the encoded protein. pk855_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pk855_1 protein").

The nucleotide sequence of pk855_1 as presently determined is reported in SEQ ID NO:13, and includes a poly(A) tail. What applicants presently believe to be the proper
25 reading frame and the predicted amino acid sequence of the pk855_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14. Amino acids 29 to 41 of SEQ ID NO:14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 42. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain
30 should the predicted leader/signal sequence not be separated from the remainder of the pk855_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pk855_1 should be approximately 1400 bp.

The nucleotide sequence disclosed herein for pk855_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pk855_1 demonstrated at least some similarity with sequences identified as AA236320 (zr53h03.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 5 667157 5'), AA491296 (aa53d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE:824645 3'), and W76249 (zd66e06.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 345634 5'). Based upon sequence similarity, pk855_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the pk855_1 10 protein sequence centered around amino acid 78 of SEQ ID NO:14. The nucleotide sequence of pk855_1 indicates that it may contain some repeat elements (including some short stretches of poly(T)).

Clone "PL776_6"

15 A polynucleotide of the present invention has been identified as clone "PL776_6". PL776_6 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. PL776_6 is a full- 20 length clone, including the entire coding sequence of a secreted protein (also referred to herein as "PL776_6 protein").

The nucleotide sequence of PL776_6 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the PL776_6 protein 25 corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 272 to 284 of SEQ ID NO:16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 285. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated 30 from the remainder of the PL776_6 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone PL776_6 should be approximately 3600 bp.

The nucleotide sequence disclosed herein for PL776_6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

FASTA search protocols. PL776_6 demonstrated at least some similarity with sequences identified as AA009770 (zi04c06.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 429802 3'), AA056343 (zl66f04.s1 Stratagene colon (#937204) Homo sapiens cDNA clone 509599 3'), AA076433 (zm19g07.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 526140 3'), AA076517 (zm19g07.r1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 526140 5'), M93661 (Rat notch 2 mRNA), and R36803 (CBS-216 Homo sapiens cDNA clone CBS-216 5' end). Based upon sequence similarity, PL776_6 proteins and each similar protein or peptide may share at least some activity.

Clone "pm4_13"

A polynucleotide of the present invention has been identified as clone "pm4_13". pm4_13 was isolated from a human fetal kidney (293 cell line) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pm4_13 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pm4_13 protein").

The nucleotide sequence of pm4_13 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pm4_13 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 49 to 61 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 62. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the pm4_13 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pm4_13 should be approximately 3100 bp.

The nucleotide sequence disclosed herein for pm4_13 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pm4_13 demonstrated at least some similarity with sequences identified as H98853 (yx15d10.s1 Homo sapiens cDNA clone 261811 3'), R43710 (yg19f12.s1 Homo sapiens cDNA clone 32692 3'), and T22962 (Human gene signature HUMGS04687). The predicted amino acid sequence disclosed herein for pm4_13 was

searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pm4_13 protein demonstrated at least some similarity to sequences identified as U20865 (ylr246wp [Saccharomyces cerevisiae]), Z29121 (ZK757.1 [Caenorhabditis elegans]), Z46259 (N0325 gene product [Saccharomyces cerevisiae]), Z68507 (m18.8 [Caenorhabditis elegans]), and Z71602 (orf ynl326c [Saccharomyces cerevisiae]). Based upon sequence similarity, pm4_13 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the pm4_13 protein sequence, centered around amino acids 86, 184, and 225 of SEQ ID NO:18, respectively.

Clone "pt326_4"

A polynucleotide of the present invention has been identified as clone "pt326_4". pt326_4 was isolated from a human adult blood (lymphoblastic leukemia MOLT-4) cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. pt326_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "pt326_4 protein").

The nucleotide sequence of pt326_4 as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the pt326_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone pt326_4 should be approximately 3100 bp.

The nucleotide sequence disclosed herein for pt326_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. pt326_4 demonstrated at least some similarity with sequences identified as AA361324 (EST70660 T-cell lymphoma Homo sapiens cDNA 5' end), H94651 (yv19c12.s1 Homo sapiens cDNA clone 243190 3'), T22309 (Human gene signature HUMGS03882), and U17907 (Human chromosome 17q21 mRNA clone B169). The predicted amino acid sequence disclosed herein for pt326_4 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted pt326_4 protein demonstrated at least some similarity to sequences identified as D89646 (GTBP-ALT [Homo sapiens]) and U28946 (G/T mismatch binding

protein (GTBP) [Homo sapiens]). Based upon sequence similarity, pt326_4 proteins and each similar protein or peptide may share at least some activity.

Deposit of Clones

5 Clones cc359_4, ct547_2, en553_1, nn296_2, nq27_13, pk65_4, pk855_1, PL776_6, pm4_13, and pt326_4 were deposited on March 31, 1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98715, from which each clone comprising a particular polynucleotide is obtainable. All
10 restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited
15 by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector
20 was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce
25 the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

30 An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

| <u>Clone</u> | <u>Probe Sequence</u> |
|--------------|-----------------------|
| cc359_4 | SEQ ID NO:21 |
| ct547_2 | SEQ ID NO:22 |
| en553_1 | SEQ ID NO:23 |
| 5 nn296_2 | SEQ ID NO:24 |
| nq27_13 | SEQ ID NO:25 |
| pk65_4 | SEQ ID NO:26 |
| pk855_1 | SEQ ID NO:27 |
| PL776_6 | SEQ ID NO:28 |
| 10 pm4_13 | SEQ ID NO:29 |
| pt326_4 | SEQ ID NO:30 |

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these parameters:

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

The oligonucleotide should preferably be labeled with γ - ^{32}P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4×10^6 dpm/pmol.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 $\mu\text{g}/\text{ml}$. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in

fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with

known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely used for commercial, nonprofit, or academic purposes. In all search programs in the suite

-- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length
5 one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six,
10 seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

15 Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence
20 identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when
25 aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian
30 species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*,

Cricetulus griseus, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species

5 (O'Brien and Seuáñez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides

10 or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by

15 comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to

20 those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at

25 least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

| Stringency Condition | Polynucleotide Hybrid | Hybrid Length (bp) [†] | Hybridization Temperature and Buffer [†] | Wash Temperature and Buffer [†] |
|----------------------|-----------------------|---------------------------------|---|--|
| A | DNA:DNA | ≥ 50 | 65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide | 65°C; 0.3xSSC |
| B | DNA:DNA | <50 | T _B *; 1xSSC | T _B *; 1xSSC |
| C | DNA:RNA | ≥ 50 | 67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide | 67°C; 0.3xSSC |
| D | DNA:RNA | <50 | T _D *; 1xSSC | T _D *; 1xSSC |
| E | RNA:RNA | ≥ 50 | 70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide | 70°C; 0.3xSSC |
| F | RNA:RNA | <50 | T _F *; 1xSSC | T _F *; 1xSSC |
| G | DNA:DNA | ≥ 50 | 65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide | 65°C; 1xSSC |
| H | DNA:DNA | <50 | T _H *; 4xSSC | T _H *; 4xSSC |
| I | DNA:RNA | ≥ 50 | 67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide | 67°C; 1xSSC |
| J | DNA:RNA | <50 | T _J *; 4xSSC | T _J *; 4xSSC |
| K | RNA:RNA | ≥ 50 | 70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide | 67°C; 1xSSC |
| L | RNA:RNA | <50 | T _L *; 2xSSC | T _L *; 2xSSC |
| M | DNA:DNA | ≥ 50 | 50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide | 50°C; 2xSSC |
| N | DNA:DNA | <50 | T _N *; 6xSSC | T _N *; 6xSSC |
| O | DNA:RNA | ≥ 50 | 55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide | 55°C; 2xSSC |
| P | DNA:RNA | <50 | T _P *; 6xSSC | T _P *; 6xSSC |
| Q | RNA:RNA | ≥ 50 | 60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide | 60°C; 2xSSC |
| R | RNA:RNA | <50 | T _R *; 4xSSC | T _R *; 4xSSC |

[†]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†]: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

*T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,

5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or
10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an
15 expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably
20 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, *e.g.*, Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (*i.e.*, from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

5 The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies
10 or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express
15 recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare
20 with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for
25 examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those
30 described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;

Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.

Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term

tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

- 5 The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.
- 10
- 15 Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
- 20 Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and
- 25
- 30 murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune

response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2

microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (*e.g.*, B7-1, B7-2, B7-3) induces a T cell mediated
5 immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated
10 immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without
15 limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al.,
20 J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnoli et al.,
25 Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.
30

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek,

D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

- 5 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995;
- 10 Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

- Assays for lymphocyte survival/apoptosis (which will identify, among others,
- 15 proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993;
- 20 Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

- Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

25

Hematopoiesis Regulating Activity

- A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell
- 30 lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid

cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and

Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

5

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

10

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

15

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

20

25

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and

30

in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin- β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. *J. Clin. Invest.* 95:1370-1376, 1995; Lind et al.

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

5 A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting
10 formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

20 A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands,
25 receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant
30 receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160, 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this
5 recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells
10 become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas
15 to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed
20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the
25 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block
30 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical

compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in
5 combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If
10 administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical
15 composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is
20 administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
25 When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid
30 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present

invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 μg to about 100 mg (preferably about 0.1 ng to about 10 mg, more preferably about 0.1 μg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein.

Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of
5 antibody-producing hybridomas in accordance with known methods (see for example, Goding, 1983, *Monoclonal antibodies: principles and practice*, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in *Current Protocols in Immunology*, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the
10 relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, *supra*; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in *Current Protocols in Immunology*, Unit 2.8, Greene Publishing
15 Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be
20 produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild *et al.*, 1996, *Nature Biotechnology* 14: 845-851; Mendez *et al.*, 1997, *Nature Genetics* 15: 146-156 (erratum *Nature Genetics* 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide
25 immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, FEBS Lett. 211, 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful
30 diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where

abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

5 For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably
10 be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the
15 methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical
20 applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium
25 sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other
30 ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions
5 from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of
10 carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to
15 provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in
20 question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to
25 humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of
30 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect

the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

5 Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

10 Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 216 to nucleotide 2174;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 339 to nucleotide 2174;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone cc359_4 deposited under accession number ATCC 98715;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
 - (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
 - (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:1.
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.
7. An isolated polynucleotide encoding the protein of claim 6.
8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715.
9. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone cc359_4 deposited under accession number ATCC 98715;the protein being substantially free from other mammalian proteins.
10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
12. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 202 to nucleotide 414;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 370 to nucleotide 414;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ct547_2 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone ct547_2 deposited under accession number ATCC 98715;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
- (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:3.

13. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
- (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone ct547_2 deposited under accession number ATCC 98715;
the protein being substantially free from other mammalian proteins.

14. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 206 to nucleotide 415;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 293 to nucleotide 415;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone en553_1 deposited under accession number ATCC 98715;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone en553_1 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and

(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:5.

15. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone en553_1 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins.

16. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 120 to nucleotide 1202;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nn296_2 deposited under accession number ATCC 98715;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (g) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f); and
- (h) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f), and that has a length that is at least 25% of the length of SEQ ID NO:7.

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone nn296_2 deposited under accession number ATCC 98715;
- the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 597 to nucleotide 704;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nq27_13 deposited under accession number ATCC 98715;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;
- (i) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(h); and
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:9.

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence of SEQ ID NO:32;
- (d) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
- (e) the amino acid sequence encoded by the cDNA insert of clone nq27_13 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins.

20. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 44 to nucleotide 475;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk65_4 deposited under accession number ATCC 98715;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- (g) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f); and
- (h) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f), and that has a length that is at least 25% of the length of SEQ ID NO:11.

21. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
- (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone pk65_4 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins.

22. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 285 to nucleotide 590;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 408 to nucleotide 590;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pk855_1 deposited under accession number ATCC 98715;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;
- (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and

(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:13.

23. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone pk855_1 deposited under accession number ATCC 98715;
- the protein being substantially free from other mammalian proteins.

24. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 193 to nucleotide 2223;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 1045 to nucleotide 2223;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone PL776_6 deposited under accession number ATCC 98715;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
 - (j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and
 - (k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:15.
25. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:16;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone PL776_6 deposited under accession number ATCC 98715;
- the protein being substantially free from other mammalian proteins.
26. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 198 to nucleotide 1121;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 381 to nucleotide 1121;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pm4_13 deposited under accession number ATCC 98715;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone pm4_13 deposited under accession number ATCC 98715;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;

(j) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i); and

(k) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(i), and that has a length that is at least 25% of the length of SEQ ID NO:17.

27. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:18;

(b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and

(c) the amino acid sequence encoded by the cDNA insert of clone pm4_13 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins.

28. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 19 to nucleotide 1953;

(c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone pt326_4 deposited under accession number ATCC 98715;

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

(e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;

(f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;

(g) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f); and

(h) a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified in (a)-(f), and that has a length that is at least 25% of the length of SEQ ID NO:19.

29. A protein comprising an amino acid sequence selected from the group consisting of:


(a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone pt326_4 deposited under accession number ATCC 98715;

the protein being substantially free from other mammalian proteins.

FIGURE 1A




Plasmid name: pED6dpc2

Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs

Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al, 1989, Mol. Cell. Biol. 9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the Clal site. SST cDNAs are cloned between EcoRI and NotI

SEQUENCE LISTING

<110> Jacobs, Kenneth
 McCoy, John M.
 LaVallie, Edward R.
 Collins-Racie, Lisa A.
 Evans, Cheryl
 Merberg, David
 Treacy, Maurice
 Agostino, Michael J.
 Steininger II, Robert J.
 Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> GI 6067A

<140>

<141>

<160> 32

<170> PatentIn Ver. 2.0

<210> 1

<211> 2360

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (2343)

<400> 1

```

ccacttcccc cttttgttaa ttaaaactaa gaagtcggaa tgggaacgag gtgcccagct 60
cccggtggaga aagcttaagg acaccacgcc agtgetttcc tgccttcctt ccgagatgga 120
aagaggagct cctagctcac ttaagccggg gtagggctgg ttctccttcc cgagccaaaa 180
tcccaggcga tggtaatta tgaacgtgcc acaccatgaa gctcttgagg caggtaactg 240
tgcaccacca cacctggaat gccatctcgc tcccgttcgt ctacctcacg gcgcaagtgt 300
ggattctgtg tgcagccatc gctgctgcgc cctcagccgg gccccagaac tgccccctccg 360
tctgctcgtg cagtaaccag ttcagcaagg tgggtgacac gcgccggggc ctctccgagg 420
tcccgcaggg tattcctcgc aacacccggg acctcaacct catggagaac aacatccaga 480
tgatccaggc cgacacctc cgccacctcc accacctgga ggtcctgcag ttgggcagga 540
actccatccg gcagattgag gtgggggcct tcaacggcct ggccagcctc aacaccctgg 600
agctgttcga caactggctg acagtcctcc ctacgggggc ctttgaatac ctgtccaagc 660
tgccgggagct ctggcttcgc aacaacccca tcgaaagcat cccctcttac gccttcaacc 720
gggtgccctc cctcatgcgc ctggacttgg gggagctcaa gaagctggag tatatctctg 780
agggagcttt tgaggggctg ttcaacctca agtatctgaa cttgggcatg tgcaacatta 840
aagacatgcc caatctcacc cccctgttgg ggctggagga gctggagatg tcagggaacc 900
acttccttga gatcaggcct ggctccttcc atggcctgag ctccctcaag aagctctggg 960
tcatgaactc acaggtcagc ctgattgagc ggaatgcttt tgacgggctg gcttcaactg 1020
tggaactcaa cttggcccac aataacctct cttctttgcc ccatgacctc tttacccccc 1080
tgaggtagct ggtggagtgt catctacacc acaacccttg gaactgtgat tgtgacattc 1140
tgtggctagc ctggtggctt cgagagtata taccaccaa ttccacctgc tgtggccgct 1200
gtcatgctcc catgcacatg cgaggccgct acctcgtgga ggtggaccag gctccttccc 1260
agtgtcttgc ccccttcac atggacgcac ctccagacct caacatttct gagggctcga 1320
tggcagaact taagtgtcgg actcccccta tgtcctcgtg gaagtgggtg ctgccccaat 1380
ggacagtgtc cagccacgcc tcccgccacc caaggatctc tgtcctcaac gacggcacct 1440
tgaacttttc ccacgtgtg ctttcagaca ctgggggtgt cacatgcatg gtgaccaatg 1500
ttgcaggcaa ctccaacgcc tcggcctacc tcaatgtgag cacggctgag cttaacacct 1560

```

```

ccaactacag cttcttcacc acagtaacag tggagaccac ggagatctcg cctgaggaca 1620
caacgcgaaa gtacaagcct gttcctacca cgtccactgg ttaccagccg gcataatcca 1680
cctctaccac ggtgctcatt cagactaccc gtgtgcccac gcaggtggca gtacccgcga 1740
cagacaccac tgacaagatg cagaccagcc tggatgaagt catgaagacc accaagatca 1800
tcattggctg ctttgtggca gtgattgtgc tagctgccgc catgttgatt gtcttctata 1860
aacttcgtaa gcggcaccag cagcggagta cagtcacagc cgcccggaact gttgagataa 1920
tccaggtgga cgaagacatc ccagcagcaa catccgcagc agcaacagca gctccgtccg 1980
gtgtatcagg tgagggggca gtagtgctgc ccacaattca tgaccatatt aactacaaca 2040
cctacaaacc agcacatggg gccactgga cagaaaacag cctggggaac tctctgcacc 2100
ccacagtcac cactatctct gaaccttata taattcagac ccataccaag gacaaggtac 2160
aggaactca aatatgactc cctcccccaa aaaacttata aaatgcaata gaatgcacac 2220
aaagacagca actttttgtac agagtgggga gagacttttt cttgtatatg cttatatatt 2280
aagtcctatg gctggttaaa aaaaacagat tatattaaaa tttaaagaca aaaagtcaaa 2340
acnaaaaaaa aaaaaaaaaa 2360

```

```

<210> 2
<211> 653
<212> PRT
<213> Homo sapiens

```

```

<400> 2
Met Lys Leu Leu Trp Gln Val Thr Val His His His Thr Trp Asn Ala
  1              5              10              15

Ile Leu Leu Pro Phe Val Tyr Leu Thr Ala Gln Val Trp Ile Leu Cys
      20              25              30

Ala Ala Ile Ala Ala Ala Ala Ser Ala Gly Pro Gln Asn Cys Pro Ser
  35              40              45

Val Cys Ser Cys Ser Asn Gln Phe Ser Lys Val Val Cys Thr Arg Arg
  50              55              60

Gly Leu Ser Glu Val Pro Gln Gly Ile Pro Ser Asn Thr Arg Tyr Leu
  65              70              75              80

Asn Leu Met Glu Asn Asn Ile Gln Met Ile Gln Ala Asp Thr Phe Arg
      85              90              95

His Leu His His Leu Glu Val Leu Gln Leu Gly Arg Asn Ser Ile Arg
    100              105              110

Gln Ile Glu Val Gly Ala Phe Asn Gly Leu Ala Ser Leu Asn Thr Leu
    115              120              125

Glu Leu Phe Asp Asn Trp Leu Thr Val Ile Pro Ser Gly Ala Phe Glu
    130              135              140

Tyr Leu Ser Lys Leu Arg Glu Leu Trp Leu Arg Asn Asn Pro Ile Glu
    145              150              155              160

Ser Ile Pro Ser Tyr Ala Phe Asn Arg Val Pro Ser Leu Met Arg Leu
      165              170              175

Asp Leu Gly Glu Leu Lys Lys Leu Glu Tyr Ile Ser Glu Gly Ala Phe
    180              185              190

Glu Gly Leu Phe Asn Leu Lys Tyr Leu Asn Leu Gly Met Cys Asn Ile
    195              200              205

```

Lys Asp Met Pro Asn Leu Thr Pro Leu Val Gly Leu Glu Glu Leu Glu
 210 215 220
 Met Ser Gly Asn His Phe Pro Glu Ile Arg Pro Gly Ser Phe His Gly
 225 230 235 240
 Leu Ser Ser Leu Lys Lys Leu Trp Val Met Asn Ser Gln Val Ser Leu
 245 250 255
 Ile Glu Arg Asn Ala Phe Asp Gly Leu Ala Ser Leu Val Glu Leu Asn
 260 265 270
 Leu Ala His Asn Asn Leu Ser Ser Leu Pro His Asp Leu Phe Thr Pro
 275 280 285
 Leu Arg Tyr Leu Val Glu Leu His Leu His His Asn Pro Trp Asn Cys
 290 295 300
 Asp Cys Asp Ile Leu Trp Leu Ala Trp Trp Leu Arg Glu Tyr Ile Pro
 305 310 315 320
 Thr Asn Ser Thr Cys Cys Gly Arg Cys His Ala Pro Met His Met Arg
 325 330 335
 Gly Arg Tyr Leu Val Glu Val Asp Gln Ala Ser Phe Gln Cys Ser Ala
 340 345 350
 Pro Phe Ile Met Asp Ala Pro Arg Asp Leu Asn Ile Ser Glu Gly Arg
 355 360 365
 Met Ala Glu Leu Lys Cys Arg Thr Pro Pro Met Ser Ser Val Lys Trp
 370 375 380
 Leu Leu Pro Asn Gly Thr Val Leu Ser His Ala Ser Arg His Pro Arg
 385 390 395 400
 Ile Ser Val Leu Asn Asp Gly Thr Leu Asn Phe Ser His Val Leu Leu
 405 410 415
 Ser Asp Thr Gly Val Tyr Thr Cys Met Val Thr Asn Val Ala Gly Asn
 420 425 430
 Ser Asn Ala Ser Ala Tyr Leu Asn Val Ser Thr Ala Glu Leu Asn Thr
 435 440 445
 Ser Asn Tyr Ser Phe Phe Thr Thr Val Thr Val Glu Thr Thr Glu Ile
 450 455 460
 Ser Pro Glu Asp Thr Thr Arg Lys Tyr Lys Pro Val Pro Thr Thr Ser
 465 470 475 480
 Thr Gly Tyr Gln Pro Ala Tyr Thr Thr Ser Thr Thr Val Leu Ile Gln
 485 490 495
 Thr Thr Arg Val Pro Lys Gln Val Ala Val Pro Ala Thr Asp Thr Thr
 500 505 510
 Asp Lys Met Gln Thr Ser Leu Asp Glu Val Met Lys Thr Thr Lys Ile
 515 520 525

Ile Ile Gly Cys Phe Val Ala Val Ile Val Leu Ala Ala Ala Met Leu
530 535 540

Ile Val Phe Tyr Lys Leu Arg Lys Arg His Gln Gln Arg Ser Thr Val
545 550 555 560

Thr Ala Ala Arg Thr Val Glu Ile Ile Gln Val Asp Glu Asp Ile Pro
565 570 575

Ala Ala Thr Ser Ala Ala Ala Thr Ala Ala Pro Ser Gly Val Ser Gly
580 585 590

Glu Gly Ala Val Val Leu Pro Thr Ile His Asp His Ile Asn Tyr Asn
595 600 605

Thr Tyr Lys Pro Ala His Gly Ala His Trp Thr Glu Asn Ser Leu Gly
610 615 620

Asn Ser Leu His Pro Thr Val Thr Thr Ile Ser Glu Pro Tyr Ile Ile
625 630 635 640

Gln Thr His Thr Lys Asp Lys Val Gln Glu Thr Gln Ile
645 650

<210> 3

<211> 1558

<212> DNA

<213> Homo sapiens

<400> 3

```
gcgaagctga taagccaata agagtgtctgt ctagaacgca tttgcaaacc gttaagagta 60
gcttcttttt gaggccttga cttctgattc atctatagaa gtctattatg attccatcaa 120
ttgcatagct tgtgtacctg gtgaaatttg tgtcttggaa tgaccctttc gagttattga 180
catggctctg atgaatagaa catgagcccc aaactaaat ccaaaaggaa ttttctatct 240
ttcatcccc acatgtggca agacaagtgt gccctttctt acccagaggt cttttgtgtg 300
actgcatctt tctcctcctg tctccattgt gtgctttcca ttttgtcttt agtgcctata 360
ctgttaggtg ttttcttcac tggcattcac aaatttaagc cattgtctgc tcattagcct 420
tgtattttgt gtgcatatca tatatccaga cctgtatggt cactttaagc attcttatat 480
cacactgtct cctcatctac catatggtaa atgaggagac agtgtcttat atcacactgt 540
ctcctcatct accatattgt aaatgttaaa actccacatt tgtctgcac agggaaaatg 600
catgggcaca catcctccct ccctccctct ctgctctcct cccttcttc aggcctctta 660
gcattgtttg ttttccatt tctgatacta ctactccatg ctgaagattt gccatattac 720
tattttggaa acattgagtg atagaactcc tagaaaattt gcaaagaaat gttacatact 780
gtatatcaaa ctctcagatt ctagtgttga aaaagtagcc tatactttgc tattacttat 840
acctgtctgc atagaaaaaa ataagtttat tcatgacaca ttacatttg atcataaata 900
aaagaaaaaa gggcaccttt ttggagttag tcatggtagt cattagtgat atttctgaac 960
agttcttaat ttaaaatact tcaaaggaag taaaggtcat ggcttagctg aaggaaatgc 1020
tccagaaatt ggactgtgta aaccatcagt acaataatac gctgtgtatg tatgtgtata 1080
taaaatgaga attatggcat aattggagca tttgcattaa tcaacaaact cacattgaga 1140
caaaacttag ttttacagct gtcttgatta aagccaagtg ttccatgttg ctgtgaagaa 1200
tagcctcttt caaatacttt ggaaagtagt tacttggaaa cttgtaaagg tattacattt 1260
ttatatattaa acacctatag agatcttcaa ttccttgagt ctgagcttgt ggggtggaatt 1320
ctaaatttgt atcataatct gtcttttgtg aaacattttg aaaatatgta tatataatat 1380
tgtatatgca aattgtgttg tttcacttgt aaagggaata ggcttatttt tctttatatt 1440
tctgataact tgttttgcac atgaccagca ctgactgaaa ggcatgtgta gctgcaaaaca 1500
ctgttgcttt ttttgtgaaa tgaaataaaa agtattttaa tacaacaaaa aaaaaaaa 1558
```

<210> 4

<211> 71

<212> PRT

<213> Homo sapiens

<400> 4

Met Ser Pro Lys Thr Lys Ser Lys Arg Asn Phe Leu Ser Phe Ile Pro
 1 5 10 15

His Met Trp Gln Asp Lys Leu Ala Leu Ser Tyr Pro Glu Val Phe Cys
 20 25 30

Val Thr Ala Ser Phe Ser Ser Val Leu His Cys Val Leu Ser Ile Leu
 35 40 45

Ser Leu Val Pro Ile Leu Leu Gly Val Phe Phe Thr Gly Ile His Lys
 50 55 60

Phe Lys Pro Leu Leu Pro His
 65 70

<210> 5

<211> 2637

<212> DNA

<213> Homo sapiens

<400> 5

ccttgagcct gttcctttac ctcaccaggc ctcattttcc acatctgttg aacaatctgg 60
 ctcttagggc ccttttcaat tctagtgttc tggagggtcca tgaactgttt ttgtgttagta 120
 gagaagaact ttcttgaagt tcgaatataat aatatatgac agaggaaatc actgtttatga 180
 accttagagt tattcccatg ggaggatgaa gactgacatt gcttccttgc acaccaggac 240
 ttgggcctgt actgctctaa ttctgaactt aatttcctgt gtggctcttg cttggttcat 300
 gggacggtct cctaacataa tgtttatata ccgtggctca ggcatagaga cccactcatg 360
 gtttcccatc agaatttggg ttccagttca ccactccaca tacacacacc aaggctaagt 420
 attcatgcta ttgtcagttt ttgcttcttt gatattgttc tgaaggtagt ttttattgat 480
 acttctttct ttctaaagtc aatgagtaaa gttatggcaa gacattggaa agacattgca 540
 gtgctccag gctggagtgc atgactcatc tcctggcccc tcagggaac cggagaaggc 600
 agaaaagggc aagaatgttg tgttgtcttt gggctgtgga gttcatgatt atggacactt 660
 tctgaattat tggcactaag ggcacatcct gcttagcatg gaggctggac agctctggga 720
 aagcagagat tcttttttagg gagtccagag ctttttttcc ttctttctta tccctctttt 780
 ccaatagaga gtgcagaagg gtgactgta gggttgatac attatgtggt gctctgtttt 840
 tttgagcatt gtctactcag agtgattacc aagggtggagc tcattatggt acctggcacc 900
 tgcaactact tgctcatgt tggactaaag tggaaagact cctattggga attcactcag 960
 ggaggcacca ggcattgtta gaaaagcagt atcgagagc acttaagagc tgagccttgt 1020
 gatcgggttg acttgggttt atgtcctcgc actgtcgtt cctagattta tgacctcagt 1080
 ttctctcatt cttaaagtaga gacagggatg gagggtgggg agaatatgaa ttaatttga 1140
 ttaaattgga gagaatcaga agtatttatt tggaaattgt gtgaattgga gcacatgggg 1200
 aactgaaaac aaagggtgata atttatgttg ttagatgaa ctaagaataa tgaaaacagc 1260
 atgaaggatg gaatcaaatt aagtgcacac atataaagga aatggactgg taaaagctcg 1320
 agggcaagg tgtatggaga tgggaattca ggttggaaag aggtgctga tacaaggact 1380
 ggagtggga gagctgctga ccaaatgttg aaatgaagat tttttaaaaa tgggcgcttg 1440
 ttggattcag gcaagctatt ttaacccagg actcacttta attcagtcaa aatatttttt 1500
 atcttccagt tggggagggtg ttttgggaca ggaaaaaaag ggagataaga ataccatccc 1560
 agagaaagaa gagaagtatt tgcattttgt tctctagagt tgcagatata tgcgttatct 1620
 cttctatatg gtaatacatt gcaaaggaga tacagtgaag aaatgaagta aaataaaatg 1680
 tgtgtgtctt cctctcatat gcataaagga agacaatata tgttggtaac atggatttgc 1740
 ttgcattgaa gaatttttaa ggtgttattc atttaattct tatatagaca gaatttactg 1800
 agctgaaaaa gatattgcatt ttttcccttc tgtggtgtt ttttggagat gctgaatcct 1860
 tcaaaatttt tgccctggag gatattagga aatgaggtga ttttttattt attatttttt 1920
 aaggtagcag atgttcacat tggtagctag ggcacaaacg cagggtgccc aagggaagtaa 1980
 agttagagat gggggtagct agctggaggt gcaggataac gaggcgagga atgggacaaa 2040

gggaatatta tgaagtagca ggatttagtg aaaggaagca tataaaaatg gacataaggg 2100
 ccagggtcggg tgggtcacgc cctaatacct agcactttgg gaggcctagg cagggtggatc 2160
 acctaaggtc aggagttcga gaccagcctg accaacaccc gtctctacta aaagtacaaa 2220
 aattagctgg gcgtgtggcg cgtgcctgta gtcccagcta ctcaggaggc tgaggcagga 2280
 gaatcgcttg accccaggag gtggagggtg cagtgcgcgc agattgcgtc actgcactcc 2340
 agcctgggtg acagagtgg acaccgtctc aaaaacaata aaaattaaaa aaaatggaca 2400
 tatggtttat tcattgggaa gagcacctag tgttgcatg agtgtaaaaa tgttcttagc 2460
 agccaagtca ttgcagacct ttctctccta ctmtgtgttc tggcttctcat atatttttct 2520
 ttctcacaaa ttctaccatt atgatcatag ttgtattcat cttcttgagt cagctaaata 2580
 atccttatat tttgatgaaa ggtaaccttc acttccaata ttaaaaaaaaa aaaaaaa 2637

<210> 6
 <211> 70
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Lys Thr Asp Ile Ala Ser Leu His Thr Arg Thr Trp Ala Cys Thr
 1 5 10 15
 Ala Leu Ile Leu Asn Leu Ile Ser Cys Val Ala Leu Ala Trp Phe Met
 20 25 30
 Gly Arg Ser Pro Asn Ile Met Phe Ile Ser Arg Gly Ser Gly Ile Glu
 35 40 45
 Thr His Ser Trp Phe Pro Ile Arg Ile Trp Val Pro Val His His Ser
 50 55 60
 Thr Tyr Thr His Gln Gly
 65 70

<210> 7
 <211> 4398
 <212> DNA
 <213> Homo sapiens

<220>
 <221> unsure
 <222> (4338)

<400> 7
 ggcgtgggtg gctgcggcgg cggcggcggc agcggcgctc gagcgggttc tgtcagggtc 60
 agccggcggg cccctgggtt ggtccacctg caaatcgcg agcggcgccc cagggtatcga 120
 tggcgatgaa ctataacgcg aaggatgaag tggacgggtg gccccgtgt gctccggggg 180
 gcaccgcgaa gactcggaga ccggataaca cggccttcaa acagcaacgg ctgccagctt 240
 ggcagcccat ccttacggct ggcacgggtg tacctatctt cttcatcatc ggtctcatct 300
 tcattcccat cggcattggc atttttgta cctccaacaa catccgcgag atcgagattg 360
 attataccgg aacagagcct tccagtcctt gtaataaatg tttatctccg gatgtgacac 420
 cttgcttttg taccattaac ttcacactgg aaaagtcatt tgagggaac gtgtttatgt 480
 attatggact gtctaatttc tatcaaaacc atcgtcgta cgtgaaatct cgagatgata 540
 gtcaactaaa tggagattct agtgccttgc ttaatcccag taaggaaatg gaaccttacc 600
 gaagaaatga agacaaacca attgctcctt gtggagctat tgccaacagc atgtttaatg 660
 atacattaga attgtttctc attggcaatg attcttatcc tatacctatc gctttgaaaa 720
 agaaaggatg tgcttggttg acagataaaa atgtgaaatt cagaaatccc cctggaggag 780
 acaacctgga agaagcattt aaaggtacaa caaagcctgt gaactggctt aaaccagttt 840
 acatgctgga ttctgacca gataataatg gattcataaa tgaggatttt attgtttgga 900
 tgcgtactgc agcattacct acttttcgca agttgtatcg tcttatagaa aggaaaagtg 960
 atttacatcc aacattacca gctggccgat actctttgaa tgtcacatac aattaccctg 1020

<210> 8
<211> 361

<212> PRT

<213> Homo sapiens

<400> 8

```

Met Ala Met Asn Tyr Asn Ala Lys Asp Glu Val Asp Gly Gly Pro Pro
 1             5             10             15

Cys Ala Pro Gly Gly Thr Ala Lys Thr Arg Arg Pro Asp Asn Thr Ala
 20             25             30

Phe Lys Gln Gln Arg Leu Pro Ala Trp Gln Pro Ile Leu Thr Ala Gly
 35             40             45

Thr Val Leu Pro Ile Phe Phe Ile Ile Gly Leu Ile Phe Ile Pro Ile
 50             55             60

Gly Ile Gly Ile Phe Val Thr Ser Asn Asn Ile Arg Glu Ile Glu Ile
 65             70             75             80

Asp Tyr Thr Gly Thr Glu Pro Ser Ser Pro Cys Asn Lys Cys Leu Ser
 85             90             95

Pro Asp Val Thr Pro Cys Phe Cys Thr Ile Asn Phe Thr Leu Glu Lys
100             105             110

Ser Phe Glu Gly Asn Val Phe Met Tyr Tyr Gly Leu Ser Asn Phe Tyr
115             120             125

Gln Asn His Arg Arg Tyr Val Lys Ser Arg Asp Asp Ser Gln Leu Asn
130             135             140

Gly Asp Ser Ser Ala Leu Leu Asn Pro Ser Lys Glu Cys Glu Pro Tyr
145             150             155             160

Arg Arg Asn Glu Asp Lys Pro Ile Ala Pro Cys Gly Ala Ile Ala Asn
165             170             175

Ser Met Phe Asn Asp Thr Leu Glu Leu Phe Leu Ile Gly Asn Asp Ser
180             185             190

Tyr Pro Ile Pro Ile Ala Leu Lys Lys Lys Gly Ile Ala Trp Trp Thr
195             200             205

Asp Lys Asn Val Lys Phe Arg Asn Pro Pro Gly Gly Asp Asn Leu Glu
210             215             220

Glu Arg Phe Lys Gly Thr Thr Lys Pro Val Asn Trp Leu Lys Pro Val
225             230             235             240

Tyr Met Leu Asp Ser Asp Pro Asp Asn Asn Gly Phe Ile Asn Glu Asp
245             250             255

Phe Ile Val Trp Met Arg Thr Ala Ala Leu Pro Thr Phe Arg Lys Leu
260             265             270

Tyr Arg Leu Ile Glu Arg Lys Ser Asp Leu His Pro Thr Leu Pro Ala
275             280             285

Gly Arg Tyr Ser Leu Asn Val Thr Tyr Asn Tyr Pro Val His Tyr Phe
290             295             300

```

Asp Gly Arg Lys Arg Met Ile Leu Ser Thr Ile Ser Trp Met Gly Gly
305 310 315 320

Lys Asn Pro Phe Leu Gly Ile Ala Tyr Ile Ala Val Gly Ser Ile Ser
325 330 335

Phe Leu Leu Gly Val Val Leu Leu Val Ile Asn His Lys Tyr Arg Asn
340 345 350

Ser Ser Asn Thr Ala Asp Ile Thr Ile
355 360

<210> 9

<211> 777

<212> DNA

<213> Homo sapiens

<400> 9

```

agaaattata gagtgagtgt attttccttg tgtatatatt aaacacacccc atacaaacat 60
tggttaaagtt gattacatca aagaatcttt agcttatctt ttgaagctac tggatattat 120
tggtctctct aggtttttat ataaatagtg aaatctgaat tactgaaaac catgttaatt 180
tttagaactc attttcctca gtagagacta gtgatgcatt agcttctggg aacaaacttg 240
tatcggttct taattaaatt atccaaaacg gaggcattta aacacttggg ttacaccag 300
tcttttgtgt ttgcttttta aaataaagtg ctcgattttg tattctccat attttggagt 360
aattatctac atgatgttta tagttcctgt ggtttttcac ccaagaagca gaatctcatt 420
cagtacattt agttttataa gagtcatgaa gctaaatcct tgggctatgt cagaggcaca 480
aagtctagaa tgtgtgtatt cacaatgggt tatgtacatt ttgtgecttg attcacttag 540
aagtgtctca gaaaacctgg acagtctgct tctacacaag aattttatat gtatttatga 600
agatgattct gtaccctagt atatcttttt gggcatggac taatttgtat ctgtttaact 660
catattctgc acgatctgta tatagtacat caaacttaga ggtgtgacct taaatttaac 720
tttttttaaa aactggggagg tcaataaaat ttaaactgct taaaaaaaaa aaaaaaa 777

```

<210> 10

<211> 36

<212> PRT

<213> Homo sapiens

<400> 10

Met Lys Met Ile Leu Tyr Pro Ser Ile Ser Phe Trp Ala Trp Thr Asn
1 5 10 15

Leu Tyr Leu Phe Asn Ser Tyr Ser Ala Arg Ser Val Tyr Ser Thr Ser
20 25 30

Asn Leu Glu Val
35

<210> 11

<211> 1378

<212> DNA

<213> Homo sapiens

<400> 11

```

ctccgctggc aacggcgccg ctccccgctc ctccctccca gccatggcgt tcacgttcgc 60
ggcctttctg tacatgctgg cgctgctgct cactgccgcg ctcatcttct tcgccatttg 120
gcacattata gcatttgatg agctgaagac tgattacaag aatcctatag accagtgtaa 180
taccctgaat cccctgttac tcccagagta cctcatccac gctttcttct gtgtcatgtt 240

```

```

tctttgtgca gcagagtggc ttacactggg tctcaatatg cccctcttgg catatcatat 300
ttggaggtat atgagtagac cagtgatgag tggcccagga ctctatgacc ctacaaccat 360
catgaatgca gatattctag catattgtca gaaggaagga tgggtgcaaat tagcttttta 420
tcttctagca tttttttact acctatatgg catgatctat gttttggtga gctcttagaa 480
caacacacag aagaattggg ccagttaagt gcatgcaaaa agccaccaa tgaagggatt 540
ctatccagca agatccctgc caagagtagc ctgtggaatc tgatcagtta ctttaaaaaa 600
tgactcctta ttttttaaat gtttccacat ttttgcttgt ggaagactg ttttcatatg 660
ttatactcag ataaagattt taaatggat tacgtataaa ttaataaaa atgattacct 720
ctggtgtgca cagggtttgaa cttgcacttc ttaaggaaca gccataatcc tctgaatgat 780
gcattaatta ctgactgtcc tagtacattg gaagcttttg tttataggaa cttgtagggc 840
tcatttttgg ttcatgaaa cagtatctaa ttataaatta gctgtagata tcagggtgctt 900
ctgatgaagt gaaaatgtat atctgactag tgggaaactt catgggtttc ctcactctgc 960
atgtcgatga ttatatatgg atacatttac aaaaataaaa agcgggaatt ttcccttcgc 1020
ttgaatatta tccctgtata ttgcatgaat gagagatttc ccataatttc atcagagtaa 1080
taaatatact tgctttaatt cttaagcata agtaaacatg atataaaaat atatgctgaa 1140
ttacttgtga agaatgcatt taaagctatt ttaaagtgtg ttttatttgt aagacattac 1200
ttattaagaa attggttatt atgcttactg ttctaactctg gtggtaaagg tattcttaag 1260
aatttgcagg tactacagat tttcaaaact gaatgagaga aaattgtata accatcctgc 1320
tgttccttta gtgcaatata ataaaactct gaaattaaga ctcaaaaaaa aaaaaaaa 1378

```

<210> 12

<211> 144

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Ala Phe Thr Phe Ala Ala Phe Cys Tyr Met Leu Ala Leu Leu Leu
  1              5              10              15

```

```

Thr Ala Ala Leu Ile Phe Phe Ala Ile Trp His Ile Ile Ala Phe Asp
      20              25              30

```

```

Glu Leu Lys Thr Asp Tyr Lys Asn Pro Ile Asp Gln Cys Asn Thr Leu
      35              40              45

```

```

Asn Pro Leu Val Leu Pro Glu Tyr Leu Ile His Ala Phe Phe Cys Val
      50              55              60

```

```

Met Phe Leu Cys Ala Ala Glu Trp Leu Thr Leu Gly Leu Asn Met Pro
      65              70              75              80

```

```

Leu Leu Ala Tyr His Ile Trp Arg Tyr Met Ser Arg Pro Val Met Ser
      85              90              95

```

```

Gly Pro Gly Leu Tyr Asp Pro Thr Thr Ile Met Asn Ala Asp Ile Leu
      100             105             110

```

```

Ala Tyr Cys Gln Lys Glu Gly Trp Cys Lys Leu Ala Phe Tyr Leu Leu
      115             120             125

```

```

Ala Phe Phe Tyr Tyr Leu Tyr Gly Met Ile Tyr Val Leu Val Ser Ser
      130             135             140

```

<210> 13

<211> 1450

<212> DNA

<213> Homo sapiens

<400> 13

cgaaaatgtc aagagaaagg ccaaagattt gtactttttc acttacaaag cactcctttt 60
 tcccttaaac ttctttctgt caaatttagat ttaatgagag agtactattt ttaaggagct 120
 atctgtttat gtagaatgat ttgtttaaga gtaatgtaaa ctattattga gtagaggcct 180
 aaagaggact gtgcattttt gctatttaaa ggaatcacaa atgatacat ttaagtgagc 240
 aaaaatgaca agttttacta gctaagtaga gaaataaatc tcaaatgcag cgctacaatt 300
 ttcattatct taagtacatt gtacatttct acagaacctg tgattattct cgcatagata 360
 ggatgggtact tgcataatgt gaattactac tgttgacagt ttccgcagaa atcctatttc 420
 agtggaccaaa cattgtggca tggcagcaaa tgccaacatt ttgtggaata gcagcaaatc 480
 tacaagagac cctgggttgt ttttcgtttt gttttctttt ttttttcccc ctctcctga 540
 atcagcaggg atggaaggag ggtagggaag ttatgaatta ctcttccag tagtagctct 600
 gaagtgtcac atttaatatc agttttttt aaacatgatt ctagttaaatt gtagaagaga 660
 gaagaaagag gaagtgttca cttttttaat aactgtattt agaaatttga tgtcttatat 720
 cagtgttctt gaggtattga tagcttgctt tatttctgcc ttacgttga cagtgttga 780
 gcagggtgaa taactagggc atatatattt tttttttt taagctgttt catgatgttt 840
 tctttggaat ttccggataa gttcaggaaa acattctgca tgttgatatc agtctgatgt 900
 acttatccat ctcatcaca acaaaaacac acagactgca ttgttagctc tgtaatcctt 960
 gaatcaggaa gtaaattttc ttcttctctg actttgacat ttagctata ctgtttccat 1020
 ttttgttttt acaaatcctt tgggtctaatt tctgtgagcc tacttatagc actggattaa 1080
 aatgtctgca tcatttcttt agttatccag ttaactttaa aactgttcta aaagtgtaaa 1140
 ccagcccatg acaggttttt gwacatgtta aagaacttca ttgttcagtt ttcatgatta 1200
 ttgtgtaagg aagactgatg tagatgttct gtgctgtcct ggaccatgtt aattacactt 1260
 acgacgtatt ttagttccac atcacaatga ttgttcccca gtgacctttt tatectttct 1320
 aggacacatt cttgtgtgtt ttgtgtgtgc agttccctt tgcatgtat tgctttgaca 1380
 actgtaattt gaatcagatc tgaaagaggt ccagaataaa atatatattt atattaaaaa 1440
 aaaaaaaaaa 1450

<210> 14

<211> 102

<212> PRT

<213> Homo sapiens

<400> 14

Met Gln Arg Tyr Asn Phe His Tyr Leu Lys Tyr Ile Val His Phe Tyr
 1 5 10 15

Arg Thr Cys Asp Tyr Ser Arg Met Ile Arg Met Val Leu Ala Tyr Gly
 20 25 30

Glu Leu Leu Leu Thr Val Ser Ala Glu Ile Leu Phe Gln Trp Thr
 35 40 45

Asn Ile Val Ala Trp Gln Gln Met Pro Thr Phe Cys Gly Ile Ala Ala
 50 55 60

Asn Leu Gln Glu Thr Leu Val Gly Phe Ser Phe Cys Phe Leu Cys Phe
 65 70 75 80

Phe Pro Leu Leu Leu Asn Gln Gln Gly Trp Lys Glu Gly Arg Glu Val
 85 90 95

Met Asn Tyr Ser Phe Gln
 100

<210> 15

<211> 3546

<212> DNA

<213> Homo sapiens

<400> 15

```

gtggaattgg acactggtgc cccaagcgag gagttgagca gtgctggaga agtaacgaaa 60
cagacagtct tacmgaagga agaggagagg agtcagccaa ctaaaacccc ttcatcttct 120
caagagcccc ctgatgaagg aacctcaggg acagatgtga acaaaggatc mtcaaagaat 180
gctttgtcct cmatggatcc tgaagtgagg cttagtagcc cccagggaa gccagaagat 240
tcattccagtg ttgatggtca gtcagtgggg actccagtgg ggccagaaac tggaggagag 300
aagaatgggc cmgaagaaga ggaagaagag gactttgatg acctcaccca agatgaggaa 360
gatgaaatgt catcagcttc tgaggaatct gtgctttctg tcccagaact ccaggaaacm 420
atggagaaac tgacttggct ggcatctgaa aggcgcagta gtcaggaggg tagtctgaa 480
gaagagaatt ctgaggagga gaactctgag ccagaagaag aggaggaga agaagcagaa 540
ggaatggaaa gctgcagaa agaggatgaa atgacggatg aagcagttgg agactctgct 600
gagaagcctc ctacttttgc ttacactgag actgctccag aagtggagac cagcagaact 660
ccaccaggag agagcatcaa agctgctgga aaaggccgga acaatcatcg agctcgcaac 720
aagcggggaa gtcgggctcg ggcagcagag gacacctcca agctgctggt gctgtatgat 780
gaggacattc tcgagcgaga tccactcagg gaggcagaag acttggcctt tgcccaagct 840
tatctgacca ggggtgcgaa agccctacaa catatccctg gcaagtatga agacttcctt 900
caagtcacatc atgaatttga gtcaagtacc cagagacgga cggctgtaga tctctacaaa 960
agcctgcaaa ttctgtcca agactggcct cagctgttga aagactttgc tgctttcctg 1020
ttacctgagc aagctctggc ctgtggatta tttaggagc agcaggcttt tgagaagagc 1080
cgcaagtctc ttgycagct ggagatttgc ttgagcagaa acccctcaca ccaccagaag 1140
attatcaagg tcttccaagg ctgtgcagac tgccttcccc aggagatcac cgagctcaag 1200
acacagatgt ggcagctcct caaggccac gaccactgc aggatgagtt ttctatcttc 1260
tttgaccact tgcgcccagc agctagccgg atgggtgact ttgaagagat caattggact 1320
gaggaagg agtatgagtt tgatggcttt gaagaagtgg ccctgcctga tgtggaagaa 1380
gaggagagc ctccaagat acccacagcc tcaaagaaca agaggaaaaa agagatcggg 1440
gtccaaaatc atgataagga gactgaatgg ccagatgggg ccaaggactg tgctgtctcc 1500
tgccatgaag aggtccaga ttccaagctg aagaagagca aaaggcggag ctgtagccac 1560
ttagcagca aggtctgtga cagcaaatcc tacaagagca aggagcccca tgagttggtg 1620
ggcagcagcc cccaccgaga ggctagctct atgcctggtg ctaaggaaagc tgggcagggc 1680
aaggatatga tggaagagga agccccagag gacgaggaga gactgaggc caccagagc 1740
aggactgtca ggaccaccag aaaggagag atgcctggtt caggattggc agtggggagc 1800
actttgccat ccctcagaa agtgactgtt acagaacggc tcttctgga tggcccacca 1860
cctcattcac cagagactcc tcaatttccc ccacaaactg gagctgtact gtacactgtt 1920
aagagaaacc aggttggggc tgaggttcgc tctgccccca aggcattccc cagacttcag 1980
aaagagaggg agggccaaaa ggagtgagtg gactcagagg ctttgatgct ggtctgggat 2040
gcatcagaaa ctgagaaatt gcctggatcc gtgggaaccc cctgcttctc tctgagtc 2100
tgtttctcct aagaccagag atgcaggag aagacatgtg tccgggaaac cagacactca 2160
agagagatgg ctgcccctca gcagagctcg ggtgaagaca agagacagga cgtgccctgt 2220
ccatgaatct ccatcaggaa ttgacacctc agagacttct cccaaagccc ctgagggggg 2280
tttggtctaa gacagtggaa cacaggccaa ggtccagag ggggagcagc agccaaaggc 2340
cgcagaagct acggtgtgtg ccaacaacag caaggtcagc tccactgggg aaaaggttgt 2400
cctgtggaca agggagctg accgtgtgat cctcaccatg tgccaggagc aaggggcaca 2460
gccacagacc ttcaacatca tctccagca gctgggaaat aagaccctgt ctgaggtttc 2520
ccaccgtttt cgagaactca tgcagctctt ccacactgcc tgtgaagcca gctctgagga 2580
tgaggatgat gcaaccagta ccagcaatgc agaccagctg tctgaccatg gggaccttct 2640
gtctgaagag gagctggatg aatgagactc tgggaatcat ctacacagga ccaaacccaa 2700
caggcgccct ggcaccgggg agggggtagt tgtactctgc ttgtacagtc cttgagccca 2760
gtttacagat ctggagagca ggaggccagg acaaggacaa aggctggagg atggagtagg 2820
accagggggc tctgccatcc taggcacatc tcaaggctct ttatgaagac tttacagatg 2880
tcctctgtaa atagcatcga gagtggagtt cagctccttt ctctactttt ttttggctg 2940
atggcacata tttattgttc tgtggtctaa tcacagtgtt tctaaatgta aaaagtgc 3000
atgttggtgt agctagtccc gcgacattga gtcctctgc atgaagacac tgggctcctg 3060
catccagctg tttttattgc aaactagctc ctttctccca cactgggaac tttagtccac 3120
gaggtctgca ccaccctggt agcactgggc caggtttgt agctcctgca gcagctctgc 3180
tacgtcatcg tgctccactc cagcatccat gaagctggcc cagcgccgca agtcgagttt 3240
ggtgaggtct ctggccaagg cttccagggt ctggtgcagg gacaaagagg aacacagtgc 3300
cccaaacact gggatgctct cactgctgt ggaggagag gaaacagaga cctgtagatg 3360
gatgattatt ctgcccctgg actcgccaaa ctgataagga agtccaacct tagtagactt 3420
gattgtaaac tcaacaaatt tgggtgattg tccccctagt acaccagtag tccagaggaa 3480
gaatgctttt cttgggagcc ataggggtgaa taaaggaatg ttaactgtg aaaaaaaaaa 3540
aaaaaa

```

<210> 16

<211> 677

<212> PRT

<213> Homo sapiens

<400> 16

Met Asp Pro Glu Val Arg Leu Ser Ser Pro Pro Gly Lys Pro Glu Asp
 1 5 10 15

Ser Ser Ser Val Asp Gly Gln Ser Val Gly Thr Pro Val Gly Pro Glu
 20 25 30

Thr Gly Gly Glu Lys Asn Gly Pro Glu Glu Glu Glu Glu Asp Phe
 35 40 45

Asp Asp Leu Thr Gln Asp Glu Glu Asp Glu Met Ser Ser Ala Ser Glu
 50 55 60

Glu Ser Val Leu Ser Val Pro Glu Leu Gln Glu Thr Met Glu Lys Leu
 65 70 75 80

Thr Trp Leu Ala Ser Glu Arg Arg Met Ser Gln Glu Gly Glu Ser Glu
 85 90 95

Glu Glu Asn Ser Gln Glu Glu Asn Ser Glu Pro Glu Glu Glu Glu
 100 105 110

Glu Glu Ala Glu Gly Met Glu Ser Leu Gln Lys Glu Asp Glu Met Thr
 115 120 125

Asp Glu Ala Val Gly Asp Ser Ala Glu Lys Pro Pro Thr Phe Ala Ser
 130 135 140

Pro Glu Thr Ala Pro Glu Val Glu Thr Ser Arg Thr Pro Pro Gly Glu
 145 150 155 160

Ser Ile Lys Ala Ala Gly Lys Gly Arg Asn Asn His Arg Ala Arg Asn
 165 170 175

Lys Arg Gly Ser Arg Ala Arg Ala Ser Lys Asp Thr Ser Lys Leu Leu
 180 185 190

Leu Leu Tyr Asp Glu Asp Ile Leu Glu Arg Asp Pro Leu Arg Glu Gln
 195 200 205

Lys Asp Leu Ala Phe Ala Gln Ala Tyr Leu Thr Arg Val Arg Glu Ala
 210 215 220

Leu Gln His Ile Pro Gly Lys Tyr Glu Asp Phe Leu Gln Val Ile Tyr
 225 230 235 240

Glu Phe Glu Ser Ser Thr Gln Arg Arg Thr Ala Val Asp Leu Tyr Lys
 245 250 255

Ser Leu Gln Ile Leu Leu Gln Asp Trp Pro Gln Leu Leu Lys Asp Phe
 260 265 270

Ala Ala Phe Leu Leu Pro Glu Gln Ala Leu Ala Cys Gly Leu Phe Glu
 275 280 285

Glu Gln Gln Ala Phe Glu Lys Ser Arg Lys Phe Leu Arg Gln Leu Glu
 290 295 300
 Ile Cys Phe Ala Glu Asn Pro Ser His His Gln Lys Ile Ile Lys Val
 305 310 315 320
 Leu Gln Gly Cys Ala Asp Cys Leu Pro Gln Glu Ile Thr Glu Leu Lys
 325 330 335
 Thr Gln Met Trp Gln Leu Leu Lys Gly His Asp His Leu Gln Asp Glu
 340 345 350
 Phe Ser Ile Phe Phe Asp His Leu Arg Pro Ala Ala Ser Arg Met Gly
 355 360 365
 Asp Phe Glu Glu Ile Asn Trp Thr Glu Glu Lys Glu Tyr Glu Phe Asp
 370 375 380
 Gly Phe Glu Glu Val Ala Leu Pro Asp Val Glu Glu Glu Glu Glu Pro
 385 390 395 400
 Pro Lys Ile Pro Thr Ala Ser Lys Asn Lys Arg Lys Lys Glu Ile Gly
 405 410 415
 Val Gln Asn His Asp Lys Glu Thr Glu Trp Pro Asp Gly Ala Lys Asp
 420 425 430
 Cys Ala Cys Ser Cys His Glu Gly Gly Pro Asp Ser Lys Leu Lys Lys
 435 440 445
 Ser Lys Arg Arg Ser Cys Ser His Cys Ser Ser Lys Val Cys Asp Ser
 450 455 460
 Lys Ser Tyr Lys Ser Lys Glu Pro His Glu Leu Val Gly Ser Ser Pro
 465 470 475 480
 His Arg Glu Ala Ser Pro Met Pro Gly Ala Lys Glu Ala Gly Gln Gly
 485 490 495
 Lys Asp Met Met Glu Glu Glu Ala Pro Glu Glu Arg Glu Ser Thr Glu
 500 505 510
 Ala Thr Gln Ser Arg Thr Val Arg Thr Thr Arg Lys Gly Glu Met Pro
 515 520 525
 Val Ser Gly Leu Ala Val Gly Ser Thr Leu Pro Ser Pro Arg Glu Val
 530 535 540
 Thr Val Thr Glu Arg Leu Leu Leu Asp Gly Pro Pro Pro His Ser Pro
 545 550 555 560
 Glu Thr Pro Gln Phe Pro Pro Thr Thr Gly Ala Val Leu Tyr Thr Val
 565 570 575
 Lys Arg Asn Gln Val Gly Pro Glu Val Arg Ser Cys Pro Lys Ala Ser
 580 585 590
 Pro Arg Leu Gln Lys Glu Arg Glu Gly Gln Lys Ala Val Ser Glu Ser
 595 600 605

Glu Ala Leu Met Leu Val Trp Asp Ala Ser Glu Thr Glu Lys Leu Pro
610 615 620

Gly Thr Val Gly Thr Pro Cys Phe Leu Pro Glu Ser Cys Phe Leu Lys
625 630 635 640

Asp Gln Arg Cys Arg Glu Lys Thr Cys Val Arg Glu Thr Arg His Ser
645 650 655

Arg Glu Met Ala Ala Leu Lys Gln Ser Ser Gly Glu Asp Lys Arg Gln
660 665 670

Asp Val Pro Cys Pro
675

<210> 17

<211> 3052

<212> DNA

<213> Homo sapiens

<400> 17

```

atgatgcgtc cctgcctcgg cegetgcagt cgccgcccgc gccgccgcag gccgggagga 60
gccgcagcgc cgggcgaccc cgcccgggcc tcggatccga tcacatagga cagtatgcac 120
cttaagatcc tgaagaaacg gcacaaaatg ttcaagtgat gtttagaaat aacttgtgag 180
ggtgcgtcag ggaatcatg cagccatcag gacacaggct ccgggacgtc gagcatcatc 240
ctctcctggc tgaatatgac aactatgact cttcatcgtc ctctcctcc gaggtgacg 300
tggtgcacgc ggtctggttc atccgtgacg gctgcggcat gatctgtgct gtcatgacgt 360
ggcttctggt cgcttatgca gacttcgtgg tgactttcgt catgtgctg cttccaaag 420
acttctggta ctctgtggtc aacggggtea tctttaactg cttggccgtg cttgccctgt 480
catcccacct gagaacctg ctcaccgacc ctggggcagt acccaaagga aacgctacga 540
aagaatacat ggagagcttg cagctgaagc ccggggaagt catctacaag tgccccaagt 600
gctgctgtat taaacccgag cgcgcccacc actgcagtat ttgcaaaaga tgtattcggg 660
aaatggatca tcaactgccc tggttgaaca attgtgtagg agaaaagaat caaagatttt 720
ttgtgctctt cactatgtat atagctctgt cttcagtcga tgctctgac ctttgtggat 780
ttcagttcat ctctgtgtc cgagggcagt ggactgaatg cagtgtattt tcacctccga 840
taactgtaat cctgttgatc ttctgtgcc ttgagggctt tctgtttttc actttcactg 900
cagttatggt tggcacccaa atccactcca tatgcaacga cgagacggag atcgagcgat 960
tgaaaagtga gaagcccaca tgggagcgga ggctgcgatg ggaagggatg aagtcctct 1020
ttggggggcc cccctcactc ctctggatga atccctttgt gggcttccga tttagggcag 1080
tgcccacgag acccagaaaa ggtggcccgc agttctcagt gtgaggcgtg gtcacacga 1140
ctgaaacttg ctacacagact tccagttatt tatttgggt ctgaaggata tcaacagctc 1200
atctgtgacc aacagggcaa ctggaacctc cacaaccaa ttgcttgag caagcagagt 1260
tttatatatt tatagtcaca gatggcagag gaagaggctc tcagtcccca cctgtacaac 1320
aacggaaaagg tgtgtggcca cacgaagaag ccaaacgccg tggcctcctg cagagctggg 1380
gcttctgtgg agaatacttc gggttattac atgggttatt caaatcctgg gtcctgagct 1440
gctgtttcca atcatgaaga aaaacagtga atccagtga cagggattct ccaagcagtc 1500
atttcagggg gctcctgctg accccgccac tcagcagtcg actccccgga tcacagcagg 1560
gcgtttacat agaaagacgt tttggtctcg attagctccg atgctttgca ctgaagttgc 1620
aaaagatctg tgcactgaac agtgaagggt gcttccggca cactccccgc tgccccgga 1680
gagacatcct ttgacctct cagcaagtct gtgtgtgtgc gtgtctgtgc gtgtgcgcgc 1740
gtgtgtgcat gtgtgtcaaa attgccagt ttgtttaggc aatgtaacat ttaccggctg 1800
tgtacagcaa acaagctatt ttttagaaac cgacgtttca gggaagaggg gagagagccg 1860
cggggtcctg cccgtgggta ctatgaatgt attgctgttg gaggacatct cgatccaaag 1920
aacagccgtt cctgtgcggc ccttcgttgc cctcctgctt tcatttttta aagaaatctt 1980
gagtgcctga gggccttgga actgattttt ttttttgtt ccagccaaat tagcagtgtg 2040
taaatggcac ctaggtaaga gcagagctgc ggctcgttga cttgataact ggggcagccc 2100
gatgctctgt gtggggcagg ggaggcatcc ttactggaga ggcagggccc agccattggg 2160
cacctctggg aaggggaggg gaccatgagg cagccagccc ctggcagggg cgactgtgcc 2220

```



```

accgcaggca gcgctccagt cgggaatggc caggatggcg cccctctgtt ggagtttttg 2280
gttagctttt acgttttttt ctcccaccac ggcacagggtg ataaaatagg atccttggtg 2340
cggagcttaa aattatgcca gaaagccaac agctcccctc gtggggcctt gccttaaaact 2400
tgcttggttt gtacattttt tgccggacgc atcaagaagc aatctgtgac aaagtctgag 2460
ggtcttcctt tatgcttgcc ctccacatta agagaagttg ggtctccctc ctgggaattg 2520
tttgcccttt ctgttcattt gtgaactgtt ttttgttttt aattactctg taccatcc 2580
gaatcagggc ttctaccact gctgatgcaa aaccacaaag ggacctacct gagccaccgt 2640
cctagccaag cgagcaaacc tgcagggggt ttggaagtgg acttggtcac cgcagaagcg 2700
tgtgcgccgt tgggggaaga gctgcgtcac agccagaggg acaaagtgtg ggtgatcctg 2760
gagacgccag ttccgagat tggtctgcat attcatttgc acattgttgt ctgggttgga 2820
catgcgtgtg ggcttcagtg tgaggctttt aatatgtata tcctgttatc aataaaacaa 2880
ttatccaagt ggttgaatcc tgtgagactt ggcaagtgtg tgcaaatcaa gtatactga 2940
cttttcaacc tcttctttca atgtaacttt tatatgaaat aaagtaatca attaacagtt 3000
ctcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 3052

```

<210> 18

<211> 308

<212> PRT

<213> Homo sapiens

<400> 18

```

Met Gln Pro Ser Gly His Arg Leu Arg Asp Val Glu His His Pro Leu
  1             5             10             15

```

```

Leu Ala Glu Asn Asp Asn Tyr Asp Ser Ser Ser Ser Ser Ser Ser Glu
          20             25             30

```

```

Ala Asp Val Ala Asp Arg Val Trp Phe Ile Arg Asp Gly Cys Gly Met
  35             40             45

```

```

Ile Cys Ala Val Met Thr Trp Leu Leu Val Ala Tyr Ala Asp Phe Val
  50             55             60

```

```

Val Thr Phe Val Met Leu Leu Pro Ser Lys Asp Phe Trp Tyr Ser Val
  65             70             75             80

```

```

Val Asn Gly Val Ile Phe Asn Cys Leu Ala Val Leu Ala Leu Ser Ser
          85             90             95

```

```

His Leu Arg Thr Met Leu Thr Asp Pro Gly Ala Val Pro Lys Gly Asn
 100             105             110

```

```

Ala Thr Lys Glu Tyr Met Glu Ser Leu Gln Leu Lys Pro Gly Glu Val
 115             120             125

```

```

Ile Tyr Lys Cys Pro Lys Cys Cys Cys Ile Lys Pro Glu Arg Ala His
 130             135             140

```

```

His Cys Ser Ile Cys Lys Arg Cys Ile Arg Lys Met Asp His His Cys
 145             150             155             160

```

```

Pro Trp Val Asn Asn Cys Val Gly Glu Lys Asn Gln Arg Phe Phe Val
          165             170             175

```

```

Leu Phe Thr Met Tyr Ile Ala Leu Ser Ser Val His Ala Leu Ile Leu
          180             185             190

```

```

Cys Gly Phe Gln Phe Ile Ser Cys Val Arg Gly Gln Trp Thr Glu Cys
          195             200             205

```

Ser Asp Phe Ser Pro Pro Ile Thr Val Ile Leu Leu Ile Phe Leu Cys
 210 215 220

Leu Glu Gly Leu Leu Phe Phe Thr Phe Thr Ala Val Met Phe Gly Thr
 225 230 235 240

Gln Ile His Ser Ile Cys Asn Asp Glu Thr Glu Ile Glu Arg Leu Lys
 245 250 255

Ser Glu Lys Pro Thr Trp Glu Arg Arg Leu Arg Trp Glu Gly Met Lys
 260 265 270

Ser Val Phe Gly Gly Pro Pro Ser Leu Leu Trp Met Asn Pro Phe Val
 275 280 285

Gly Phe Arg Phe Arg Arg Leu Pro Thr Arg Pro Arg Lys Gly Gly Pro
 290 295 300

Glu Phe Ser Val
 305

<210> 19
 <211> 3123
 <212> DNA
 <213> Homo sapiens

<400> 19
 ggatgctgga gcagaacaat ggatttctct ttctctttca tgcaagggat catgggaaac 60
 acaattcagc aaccacctca actcattgac tccgccaaca tccgtcagga ggatgccttt 120
 gataacaaca gtgacattgc tgaagatggg gccagacac catatgaagc tactttgcag 180
 caaggctttc agtaccagc tacaacagaa gatcttctc cactcacaaa tgggtatcca 240
 tcataatca gtgtgtatga aactcaaacc aaataccagt catataatca gtatcctaata 300
 gggtcagcca atggctttgg tgcagttaga aacttttagc cactgacta ttatcattca 360
 gaaattccaa acacaagacc acatgaaatt ctggaaaaac cttccctcc acagccacca 420
 cctctcctt cgggtaccaca aactgtgatt ccaaagaaga ctggctcacc tgaaattaaa 480
 ctaaaaataa ccaaaactat ccagaatggc agggaattgt ttgagcttc cctttgtgga 540
 gaccttttaa atgaagtaca ggcaagttag cacacgaaat caaagcatga aagcagaaaa 600
 gaaaagagga aaaaaagcaa caagcatgac tcatcaagat ctgaagagcg caagtacac 660
 aaaatcccca aattagaacc agaggaacaa aatagaccaa atgagagggg tgacactgta 720
 tcagaaaaac caagggaaga accagtacta aaagaggaag cccagttca gccataacta 780
 tctctgttc caacaacgga agtgtccact ggtgttaagt ttcaggttg cgatcttggt 840
 tgggtccaagg tgggaacctt tcttgggtgg ccttgtatgg tttcaagtga tccccagctt 900
 gaggttcata ctaaaattaa cacaagaggt gcccgagaat atcatgtcca gttttttagc 960
 aaccagccag agagggcggt ggttcatgaa aaacgggtac gagagtataa aggtcataaa 1020
 cagtatgaag aattactggc tgaggcaacc aaacaagcca gcaatcactc tgagaaacaa 1080
 aagattcggg aaccccgacc tcagagagaa cgtgctcagt ggatattgg cattgcccac 1140
 gcagagaaag cattgaaat gactcgagaa gaaagaatag aacagtatac ttttatttac 1200
 attgataaac agcctgaaga ggctttatcc caagcaaaaa agagtgttg ctccaaaacc 1260
 gaagttaaaa aaaccgagc accaagatct gtgctgaata ctgagccaga acagaccaat 1320
 gcaggggagg tggctctctc actctcaagt actgaaatc ggagacatag ccagaggcgg 1380
 cacacaagtg cggaagagg agagccaccg cctgttaaaa tagcctggaa aactgcggca 1440
 gcaaggaaat cttaccagc ttccattacg atgcacaaag ggagcctgga ttgcagaag 1500
 tgtaacatgt ctccagttgt gaaaattgaa caagtgtttg ctcttcagaa tgctacaggg 1560
 gatgggaaat ttatcgatca atttgtttat tcaacaaagg gaattggtaa caaacagaa 1620
 ataagtgtca gggggcaaga caggcttata atttctacac caaaccagag aaatgaaaag 1680
 ccaacgcaga gtgtatcatc tctgaagca acatctggtt ctacaggctc agtagaaaag 1740
 aagcaacaga gaagatcaat tagaactcgt tctgaatcag agaaatccac tgaggttggt 1800
 ccaaagaaga agatcaaaaa ggagcaggtt gaaacagttc ctgaggtac agtgaagact 1860
 ggattacaga aagggtcggc ggaccgggga gtgcagggt ctgtcagatt cagtgcagc 1920

```

tccgtctccg cagcgattga ggaactgtg gactgagatt cctgtacaat ttcacccag 1980
aaactccaga cttgtagtct ccattgcaaga tttctttgtc ggcggcttga taaacagttt 2040
ctttgttttc gattttgatt tcgccaatca tcattattgg cattttcctg cctggtttct 2100
tcttcaagac tctgaacaat tgctttaaca gtcaaatgat ttttttttc ggtttgagct 2160
ggatgggtac agcttaaatc atgggtccag cctaaaaacc accatttaac ttacactgat 2220
caatttcaac atggactgtt tttggttttt tgtttttaaa taaagcatca ttaatgcaca 2280
tctgcagggg tttgccaac agcccaaact gtatacatta caatcattaa aagttcttat 2340
tttttttaat attagtgcg ttatcatgga gaacagcatg acagctgtct ttggcagtct 2400
gtcatttttc tagcattttc agaaactcat cggaaatggc ggtacctgtg tttcccttcg 2460
aaagcctctc agtacagcac tcctgttctc ctgttaaaac tccttgtaa tccagtgatc 2520
tttttagcca aggaaatatt ttgtgatggg gttctgggtc catacaccag caatgaagga 2580
gatagatttg tgtacttggt ttttttaate agcattaaca tgggcaggca ccctcattta 2640
tagatgtcag gaaacattca gtgaaaaact tgtagaatgg gatgtgataa cgaggttcca 2700
gtaattctgag cagtctaacg aggccacct cctccaccac agaactggc tatgttccaa 2760
gtgctactct cactcagcct gttgcggatc ttcattggcct caggagactt gttctccat 2820
gggctcttct ggactgcaca ctccaccat agcttgctgg gttgatctag atgtctgtt 2880
gttgtagtga aattttgggg gaaaaaatcc aaaacacaaa ctgtgggttg aaatattaac 2940
cgtctccttg gttccttggt attcacctg cctgatctgc acatttcac gtggctgtt 3000
ctgtatagcc tatactgat tagcccaaga gattgttgc ttgtaacttt ttgcactatt 3060
gttttggtg gatttgtatt acacacagtt ttaaaaaaaa caataaaaaa aaaaaaaaaa 3120
aaa 3123

```

<210> 20

<211> 645

<212> PRT

<213> Homo sapiens

<400> 20

```

Met Asp Phe Ser Phe Ser Phe Met Gln Gly Ile Met Gly Asn Thr Ile
  1             5             10             15

```

```

Gln Gln Pro Pro Gln Leu Ile Asp Ser Ala Asn Ile Arg Gln Glu Asp
      20             25             30

```

```

Ala Phe Asp Asn Asn Ser Asp Ile Ala Glu Asp Gly Gly Gln Thr Pro
    35             40             45

```

```

Tyr Glu Ala Thr Leu Gln Gln Gly Phe Gln Tyr Pro Ala Thr Thr Glu
    50             55             60

```

```

Asp Leu Pro Pro Leu Thr Asn Gly Tyr Pro Ser Ser Ile Ser Val Tyr
    65             70             75             80

```

```

Glu Thr Gln Thr Lys Tyr Gln Ser Tyr Asn Gln Tyr Pro Asn Gly Ser
      85             90             95

```

```

Ala Asn Gly Phe Gly Ala Val Arg Asn Phe Ser Pro Thr Asp Tyr Tyr
    100             105             110

```

```

His Ser Glu Ile Pro Asn Thr Arg Pro His Glu Ile Leu Glu Lys Pro
    115             120             125

```

```

Ser Pro Pro Gln Pro Pro Pro Pro Pro Ser Val Pro Gln Thr Val Ile
    130             135             140

```

```

Pro Lys Lys Thr Gly Ser Pro Glu Ile Lys Leu Lys Ile Thr Lys Thr
    145             150             155             160

```

```

Ile Gln Asn Gly Arg Glu Leu Phe Glu Ser Ser Leu Cys Gly Asp Leu
    165             170             175

```

Leu Asn Glu Val Gln Ala Ser Glu His Thr Lys Ser Lys His Glu Ser
 180 185 190
 Arg Lys Glu Lys Arg Lys Lys Ser Asn Lys His Asp Ser Ser Arg Ser
 195 200 205
 Glu Glu Arg Lys Ser His Lys Ile Pro Lys Leu Glu Pro Glu Glu Gln
 210 215 220
 Asn Arg Pro Asn Glu Arg Val Asp Thr Val Ser Glu Lys Pro Arg Glu
 225 230 235 240
 Glu Pro Val Leu Lys Glu Glu Ala Pro Val Gln Pro Ile Leu Ser Ser
 245 250 255
 Val Pro Thr Thr Glu Val Ser Thr Gly Val Lys Phe Gln Val Gly Asp
 260 265 270
 Leu Val Trp Ser Lys Val Gly Thr Tyr Pro Trp Trp Pro Cys Met Val
 275 280 285
 Ser Ser Asp Pro Gln Leu Glu Val His Thr Lys Ile Asn Thr Arg Gly
 290 295 300
 Ala Arg Glu Tyr His Val Gln Phe Phe Ser Asn Gln Pro Glu Arg Ala
 305 310 315 320
 Trp Val His Glu Lys Arg Val Arg Glu Tyr Lys Gly His Lys Gln Tyr
 325 330 335
 Glu Glu Leu Leu Ala Glu Ala Thr Lys Gln Ala Ser Asn His Ser Glu
 340 345 350
 Lys Gln Lys Ile Arg Lys Pro Arg Pro Gln Arg Glu Arg Ala Gln Trp
 355 360 365
 Asp Ile Gly Ile Ala His Ala Glu Lys Ala Leu Lys Met Thr Arg Glu
 370 375 380
 Glu Arg Ile Glu Gln Tyr Thr Phe Ile Tyr Ile Asp Lys Gln Pro Glu
 385 390 395 400
 Glu Ala Leu Ser Gln Ala Lys Lys Ser Val Ala Ser Lys Thr Glu Val
 405 410 415
 Lys Lys Thr Arg Arg Pro Arg Ser Val Leu Asn Thr Gln Pro Glu Gln
 420 425 430
 Thr Asn Ala Gly Glu Val Ala Ser Ser Leu Ser Ser Thr Glu Ile Arg
 435 440 445
 Arg His Ser Gln Arg Arg His Thr Ser Ala Glu Glu Glu Glu Pro Pro
 450 455 460
 Pro Val Lys Ile Ala Trp Lys Thr Ala Ala Ala Arg Lys Ser Leu Pro
 465 470 475 480
 Ala Ser Ile Thr Met His Lys Gly Ser Leu Asp Leu Gln Lys Cys Asn
 485 490 495

Met Ser Pro Val Val Lys Ile Glu Gln Val Phe Ala Leu Gln Asn Ala
500 505 510

Thr Gly Asp Gly Lys Phe Ile Asp Gln Phe Val Tyr Ser Thr Lys Gly
515 520 525

Ile Gly Asn Lys Thr Glu Ile Ser Val Arg Gly Gln Asp Arg Leu Ile
530 535 540

Ile Ser Thr Pro Asn Gln Arg Asn Glu Lys Pro Thr Gln Ser Val Ser
545 550 555 560

Ser Pro Glu Ala Thr Ser Gly Ser Thr Gly Ser Val Glu Lys Lys Gln
565 570 575

Gln Arg Arg Ser Ile Arg Thr Arg Ser Glu Ser Glu Lys Ser Thr Glu
580 585 590

Val Val Pro Lys Lys Lys Ile Lys Lys Glu Gln Val Glu Thr Val Pro
595 600 605

Gln Ala Thr Val Lys Thr Gly Leu Gln Lys Gly Ser Ala Asp Arg Gly
610 615 620

Val Gln Gly Ser Val Arg Phe Ser Asp Ser Ser Val Ser Ala Ala Ile
625 630 635 640

Glu Glu Thr Val Asp
645

<210> 21
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 21
gntggcattc caggtgtggt ggtgcacag

29

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 22
cnaggctaag gaggcagcaa tggcttaaa 29

<210> 23
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 23
tcttcactgt atctcctttg c 21

<210> 24
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 24
anaactccca gaaggaagga gatggatcc 29

<210> 25
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 25
anattcttgt gtagaagcga actgtccag 29

<210> 26
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 26
anggcgaaga agatgagcgc ggcagtgag 29

<210> 27
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 27
gnaagaagtt taagggaaaa aggagtgt 29

<210> 28
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 28
cnctttttcc tcttggttctt tgaggctgt 29

<210> 29
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue

<400> 29
anggatcaga gcatggactg aagacagag 29

<210> 30
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<220>

<221> misc_feature

<222> (2)

<223> biotinylated phosphoramidite residue

<400> 30

anatagacca aatgagaggg ttgacactg

29

<210> 31

<211> 87

<212> PRT

<213> Homo sapiens

<400> 31

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Met | Gly | Ile | Gln | Val | Gly | Lys | Arg | Leu | Leu | Ile | Gln | Gly | Leu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Glu | Leu | Gly | Glu | Leu | Leu | Thr | Lys | Cys | Gly | Asn | Glu | Asp | Phe | Leu | Lys |
| | | 20 | | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Gly | Ala | Gly | Trp | Ile | Gln | Ala | Ser | Tyr | Phe | Asn | Pro | Gly | Leu | Thr |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ile | Gln | Ser | Lys | Tyr | Phe | Leu | Ser | Ser | Ser | Trp | Gly | Gly | Val | Leu |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gln | Glu | Lys | Lys | Gly | Asp | Lys | Asn | Thr | Ile | Pro | Glu | Lys | Glu | Glu |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

| | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|
| Lys | Tyr | Leu | His | Phe | Val | Leu |
| | | | | | 85 | |

<210> 32

<211> 82

<212> PRT

<213> Homo sapiens

<400> 32

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Met | Phe | Ile | Val | Pro | Val | Val | Phe | His | Pro | Arg | Ser | Arg | Ile | Ser |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Phe | Ser | Thr | Phe | Ser | Phe | Ile | Arg | Val | Met | Lys | Leu | Asn | Pro | Trp | Ala |
| | | 20 | | | | | | 25 | | | | | 30 | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Glu | Ala | Gln | Ser | Leu | Glu | Cys | Val | Tyr | Ser | Gln | Trp | Cys | Met |
| | | 35 | | | | | 40 | | | | | 45 | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Tyr | Ile | Leu | Cys | Leu | Asp | Ser | Leu | Arg | Ser | Val | Ser | Glu | Asn | Leu | Asp |
| | 50 | | | | | 55 | | | | | 60 | | | | |

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Ser | Leu | Leu | His | Lys | Asn | Phe | Ile | Cys | Ile | Tyr | Glu | Asp | Asp | Ser |
| 65 | | | | | 70 | | | | | 75 | | | | | 80 |

Val Pro

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06946

| A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :C12N 15/00, 15/12; C07K 14/00, 14/435, 7/00 US CL :435/69.1, 320.1, 325; 536/23.5, 23.1; 530/350, 300 According to International Patent Classification (IPC) or to both national classification and IPC | | |
|---|--|---|
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/69.1, 320.1, 325; 536/23.5, 23.1; 530/350, 300 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Genbank, GenEmbl, geneseq, Swissprot, pir58 | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | |
| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| X | TOUCHMAN et al. "2006 Expressed-Sequence Tags derived from human chromosome 7-enriched cDNA libraries." Genome Research. 1997, Vol.7, No.3, pages 281-292, especially Figure 3 and Genbank Accession No. G30725. | 1-3 |
| X | Database on Genbank, HILLIER et al. "ym51g12.s1 Homo sapiens cDNA clone 51970 3'." 06 July 1995, Accession No. H23117 and 23116 | 1-3 |
| X | Database on Genbank, HILLIER et al. "yg2605.r1 Homo sapiens cDNA clone 33723 5'." 14 April 1995, Accession No. R19556. | |
| X | Database on Genbank, HILLIER et al. "yj85c08.r1 Homo sapiens cDNA clone 155534 5'." 02 June 1995, Accession No. R71701. | 1-3 |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | |
| * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family | |
| Date of the actual completion of the international search 15 JUNE 1999 | | Date of mailing of the international search report 16 JUL 1999 |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230 | | Authorized officer ELIANE LAZAR-WESLEY Telephone No. (703) 308-0196 |

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/06946

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.